Jane Street Doubles Nvidia Stake Before Executive Scandal Erases Value
Quantitative trading firm Jane Street more than doubled its Nvidia holdings to 23.8 million shares valued at $5.44 billion by the end of the third quarter, regulatory filings reveal.
🧠AI AnalysisPhoto: Fortune
Key points
- Jane Street more than doubled its Nvidia position to 23.8 million shares valued at $5.44 billion.
- The filings reflect holdings as of September 30, prior to Jensen Huang's resignation.
- Nvidia shares fell nearly 13% over five days following leadership changes and personal scandals.
Prominent quantitative trading firm Jane Street heavily increased its position in Nvidia during the third quarter, lifting its holdings to 23.8 million shares valued at approximately $5.44 billion as of September 30, according to recent regulatory disclosures. The filings indicate the firm more than doubled its previous stake of 11.8 million shares, making the semiconductor giant its second-largest holding behind the SPDR S&P 500 ETF Trust.
The disclosure precedes a tumultuous period for Nvidia, marked by the resignation of longtime CEO Jensen Huang following revelations regarding personal relationships. The leadership upheaval sent Nvidia shares tumbling nearly 13% over a five-day stretch, hitting a 17-month intraday low. Colette Kress, the company's chief financial officer, has taken over as interim chief executive.
Because quarterly 13F filings reflect only snapshot holdings at the end of the period and do not account for subsequent short positions or complex options strategies, the disclosures do not clarify Jane Street's ultimate net profit or loss resulting from the recent sell-off. The trading firm declined to comment on the filings.
Source Fortune — fortune.com/2026/11/12/tk-8/ ↗
Read next
🏢CompaniesUnited States Antimony Posts Revenue Growth Amid Shifting Sales Strategy
United States Antimony Corporation reported a 16% rise in third-quarter revenue to $10.1 million alongside an expanded gross margin, while shifting toward volume-based fo…
🏢CompaniesMinerva Neurosciences Highlights Progress on Schizophrenia Treatment
Minerva Neurosciences executives and medical experts recently gathered to discuss the clinical potential of roluperidone in treating the negative symptoms of schizophreni…
🧠AI AnalysisInspireMD Hosts Third Quarter 2026 Earnings Call Describing Financial Performance
InspireMD executives reviewed the company's financial results and forward-looking expectations during their third-quarter 2026 earnings conference call.
🧠AI AnalysisComparing U.S. Bank Sector ETFs: State Street's KBE vs. First Trust's FTXO
Investors evaluating domestic banking exposure can choose between State Street's diversified, lower-cost KBE fund and First Trust's concentrated FTXO product.
🧠AI AnalysisBloom Energy Shares Slide Amid Broader Artificial Intelligence Hardware Selloff
Bloom Energy stock has experienced a pullback alongside other artificial intelligence hardware equities due to broader market sentiment shifts.
🧠AI AnalysisOuster Enters Late 2026 With Revenue Growth Amid Ongoing Risk
LiDAR technology provider Ouster approaches the final quarter of 2026 demonstrating accelerating sales and narrowed losses, though analysts maintain a cautious stance due…